Arcellx Inc (ACLX)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Rami Elghandour
Employees:
80
25 WEST WATKINS MILL ROAD, SUITE A, GAITHERSBURG, MD 20878
240-723-6641

Arcellx, Inc. engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM) It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins.

Data derived from most recent annual or quarterly report
Market Cap 867.412 Million Shares Outstanding43.787 Million Avg 30-day Volume 303.495 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS
Price to Revenue0.0 Debt to Equity0.0 EBITDA0
Price to Book Value2.261 Operating Margin0.0 Enterprise Value290.098 Million
Current Ratio13.143 EPS Growth0 Quick Ratio12.549
1 Yr BETA 0.7019 52-week High/Low 26.91 / 6.04 Profit Margin0.0
Operating Cash Flow Growth0.0 Altman Z-Score13.8619 Free Cash Flow to Firm 0
Earnings Report2022-08-11
View SEC Filings from ACLX instead.

View recent insider trading info

Funds Holding ACLX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ACLX BETA

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-06-21:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-23:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-12:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-16:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • Proxy

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    312.5 Thousand total shares from 1 transactions

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    NEW ENTERPRISE ASSOCIATES 15, L.P.

    SANDELL SCOTT D

    SONSINI PETER W.

    NEA PARTNERS 15, L.P.

    NEA 15 GP, LLC

    MAKHZOUMI MOHAMAD

    FLORENCE ANTHONY A. JR.

    BASKETT FOREST

    • 10% Owner
    6,745,262 2022-06-21 3

    GILSON MICHELLE CHIEF FINANCIAL OFFICER

    • Officer
    0 2022-05-23 2

    WARE OLIVIA C

    • Director
    0 2022-05-16 2

    NOVO HOLDINGS A/S

    • 10% Owner
    4,016,878 2022-02-08 2

    WILLIAMS LEWIS T

    • Director
    2,095,114 2022-02-08 2

    LUBNER DAVID CHARLES

    • Director
    0 2022-02-08 3

    SR ONE CAPITAL MANAGEMENT, LLC

    SR ONE CAPITAL PARTNERS I, LP

    SR ONE CAPITAL FUND I AGGREGATOR LP

    SR ONE CO-INVEST II, LLC

    GEORGE SIMEON

    SR ONE CO-INVEST II MANAGER, LLC

    • 10% Owner
    5,500,007 2022-02-08 2

    CARROLL JILL

    • Director
    5,500,007 2022-02-08 2

    THIBAULT LANCE E SEE REMARKS

    • Officer
    0 2022-02-03 1

    SR ONE CAPITAL MANAGEMENT, LLC

    SR ONE CAPITAL FUND I AGGREGATOR LP

    SR ONE CAPITAL PARTNERS I, LP

    SR ONE CO-INVEST II, LLC

    GEORGE SIMEON

    • 10% Owner
    0 2022-02-03 2

    ELGHANDOUR RAMI SEE REMARKS

    • Officer
    • Director
    0 2022-02-03 2

    BEHBAHANI ALI

    • Director
    0 2022-02-03 1

    PATEL KAVITA

    • Director
    0 2022-02-03 2

    YOON DEREK

    • Director
    0 2022-02-03 1

    HEERY CHRISTOPHER CHIEF MEDICAL OFFICER

    • Officer
    0 2022-02-03 2

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    NEW ENTERPRISE ASSOCIATES 15, L.P. - > 10% Owner

    SANDELL SCOTT D - > 10% Owner

    SONSINI PETER W. - > 10% Owner

    NEA PARTNERS 15, L.P. - > 10% Owner

    NEA 15 GP, LLC - > 10% Owner

    MAKHZOUMI MOHAMAD - > 10% Owner

    FLORENCE ANTHONY A. JR. - > 10% Owner

    BASKETT FOREST - > 10% Owner

    2022-06-23 17:10:00 -0400 2022-06-21 P 312,500 $16.00 a 6,745,262 direct 4.1272 3.7368 4.1272 2 -0.3346 3

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    ARCELLX INC ACLX 2022-08-05 22:15:04 UTC -17.1708 19.4908 600000
    ARCELLX INC ACLX 2022-08-05 21:45:03 UTC -17.1708 19.4908 600000
    ARCELLX INC ACLX 2022-08-05 21:15:03 UTC -17.1708 19.4908 600000
    ARCELLX INC ACLX 2022-08-05 20:45:04 UTC -17.1708 19.4908 600000
    ARCELLX INC ACLX 2022-08-05 20:15:05 UTC -17.1708 19.4908 600000
    ARCELLX INC ACLX 2022-08-05 19:45:04 UTC -17.1708 19.4908 600000
    ARCELLX INC ACLX 2022-08-05 19:15:05 UTC -17.1708 19.4908 600000
    ARCELLX INC ACLX 2022-08-05 18:45:04 UTC -17.1708 19.4908 600000
    ARCELLX INC ACLX 2022-08-05 18:15:03 UTC -17.1708 19.4908 600000
    ARCELLX INC ACLX 2022-08-05 17:45:04 UTC -17.1708 19.4908 600000
    ARCELLX INC ACLX 2022-08-05 17:15:04 UTC -17.1708 19.4908 600000
    ARCELLX INC ACLX 2022-08-05 16:45:05 UTC -17.19 19.51 600000
    ARCELLX INC ACLX 2022-08-05 16:15:05 UTC -17.19 19.51 600000
    ARCELLX INC ACLX 2022-08-05 15:45:04 UTC -17.19 19.51 600000
    ARCELLX INC ACLX 2022-08-05 15:15:03 UTC -17.19 19.51 600000
    ARCELLX INC ACLX 2022-08-05 14:45:04 UTC -17.19 19.51 600000
    ARCELLX INC ACLX 2022-08-05 14:15:04 UTC -17.19 19.51 600000
    ARCELLX INC ACLX 2022-08-05 13:45:05 UTC -24.6797 26.9997 200000
    ARCELLX INC ACLX 2022-08-05 13:15:04 UTC -24.6797 26.9997 200000
    ARCELLX INC ACLX 2022-08-05 12:45:05 UTC -24.6797 26.9997 200000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    Elevate your investments